V. Gruenwald Et Al. , "Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.," JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15, 2011
Gruenwald, V. Et Al. 2011. Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.. JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15 .
Gruenwald, V., Karakiewicz, P. I., Bavbek, S. E., Miller, K., Machiels, J. H., Lee, S., ... Larkin, J. M. G.(2011). Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.. JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15.
Gruenwald, V. Et Al. "Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.," JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15, 2011
Gruenwald, V. Et Al. "Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.." JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15, 2011
Gruenwald, V. Et Al. (2011) . "Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.." JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15.
@article{article, author={V. Gruenwald Et Al. }, title={Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2011}